Company Filing History:
1 out of 613 
1 out of 55 
1 out of 1,537 
Years Active: 1995-2000
Title: **Hajime Karasuyama: A Pioneer in Allergy Research**
Introduction
Hajime Karasuyama, an innovative inventor based in Tokyo, Japan, has made significant contributions to the field of allergy research. With two patented inventions to his name, his work focuses on advanced models for studying allergic reactions and incorporates cutting-edge biotechnology.
Latest Patents
His latest patents include "Transgenic Animal Allergy Models and Methods for Their Use," which introduces transgenic mice that express an antibody-type molecule encoded by a transgene. These mice exhibit an allergic reaction to specific antigens without prior sensitization, making them invaluable as allergy models. In addition, his second patent, "Recombinant Protein Receptor for IL-2," pertains to the IL-21R beta chain or its fragments, including cDNA coding, vectors, and monoclonal antibodies aimed at improving therapeutic approaches in immunology.
Career Highlights
Hajime Karasuyama has had an impactful career, working with renowned institutions such as Sankyo Company, Limited and the Tokyo Metropolitan Institute of Medical Science. His tenure at these organizations has fostered an environment of innovation, allowing for the exploration of groundbreaking concepts in medical research.
Collaborations
Throughout his career, Karasuyama has collaborated closely with esteemed colleagues, including Hiromichi Yonekawa and Choji Taya. These partnerships have facilitated shared knowledge and expertise, contributing to the advancement of their collective research endeavors.
Conclusion
Hajime Karasuyama’s inventive spirit and commitment to allergy research have positioned him as a leading figure in his field. His patented innovations not only offer new insights into allergic responses but also pave the way for future developments in therapeutic strategies aimed at improving patient outcomes. Through collaboration and pioneering research, he continues to make a significant impact on both scientific communities and public health.